Publications
| Title | Abstract | Year(sorted descending) Filter | PMID Filter |
|---|
| structure of two iron-binding proteins from bacillus anthracis. | bacillus anthracis is currently under intense investigation due to its primary importance as a human pathogen. particularly important is the development of novel anti-anthrax vaccines, devoid of the current side effects. a novel class of immunogenic bacterial proteins consists of dodecamers homologous to the dna-binding protein of escherichia coli (dps). two dps homologous genes are present in the b. anthracis genome. the crystal structures of these two proteins (dlp-1 and dlp-2) have been deter ... | 2002 | 11836250 |
| anthrax: a primary care physician's perspective. | anthrax is a disease caused by bacillus anthracis, a gram-positive, aerobic, spore-forming rod. it is also used as a biological weapon. the primary care physician will be the public's first line of defense in the event of a widespread anthrax exposure and will play a crucial role providing postexposure prophylaxis. understanding the disease process will allow the primary care physician to play an essential role in protecting and educating the public. accurate diagnosis and quick treatment will s ... | 2002 | 11837339 |
| symptoms associated with anthrax exposure: suspected "aborted" anthrax. | anthrax is a naturally occurring organism with a low incidence of infection. there are no known cases of human-to-human transmission. bioterrorism-related anthrax in the united states has been seen in three high-risk groups: (1) postal workers, (2) politicians and their staffs, and (3) the press. it appears as though the bioterrorism-related anthrax cases of fall 2001 have been transmitted through the us postal service. the authors present a case in which a person at high risk for anthrax exposu ... | 2002 | 11837340 |
| from the centers for disease control and prevention. additional options for preventive treatment for exposed persons to inhalational anthrax. | 2002 | 11838446 | |
| not every truth is good. the dangers of publishing knowledge about potential bioweapons. | 2002 | 11839688 | |
| anthrax: the hunt narrows. | 2002 | 11840859 | |
| absence of mycoplasma contamination in the anthrax vaccine. | 2002 | 11840996 | |
| anthrax-related panic is more dangerous than the disease. | 2002 | 11841857 | |
| protecting against bacillus anthracis. | 2002 | 11842520 | |
| a cure for anthrax? | 2002 | 11844555 | |
| amino acid- and purine ribonucleoside-induced germination of bacillus anthracis deltasterne endospores: gers mediates responses to aromatic ring structures. | specific combinations of amino acids or purine ribonucleosides and amino acids are required for efficient germination of endospores of bacillus anthracis deltasterne, a plasmidless strain, at ligand concentrations in the low-micromolar range. the amino acid l-alanine was the only independent germinant in b. anthracis and then only at concentrations of >10 mm. inosine and l-alanine both play major roles as cogerminants with several other amino acids acting as efficient cogerminants (his, pro, trp ... | 2002 | 11844758 |
| anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. | anthrax vaccine adsorbed (ava), an effective countermeasure against anthrax, is administered as six subcutaneous (sq) doses over 18 months. to optimize the vaccination schedule and route of administration, we performed a prospective pilot study comparing the use of fewer ava doses administered intramuscularly (im) or sq with the current schedule and route. we enrolled 173 volunteers, randomized to seven groups, who were given ava once im or sq; two doses, 2 or 4 weeks apart, im or sq; or six dos ... | 2002 | 11818160 |
| anthrax vaccine efficacy in golden syrian hamsters. | the efficacy of a licensed human anthrax vaccine (anthrax vaccine adsorbed, ava) was tested in golden syrian hamsters against a virulent bacillus anthracis spore challenge. groups of golden syrian hamsters were vaccinated at either 0 and 4 weeks or 0, 4 and 8 weeks, then challenged subcutaneously (s.c.) at 10 weeks with spores of various b. anthracis isolates. although elisa and toxin neutralization assays demonstrated high titers, none of the ava-vaccinated hamsters were protected from challeng ... | 2002 | 11818161 |
| inhalational anthrax after bioterrorism exposure: spectrum of imaging findings in two surviving patients. | the radiographic and computed tomographic (ct) findings in two patients with documented inhalational anthrax resulting from bioterrorism exposure are presented. chest radiographs demonstrated mediastinal widening, adenopathy, pleural effusions, and air-space disease. chest ct images revealed enlarged hyperattenuating mediastinal and hilar lymph nodes and edema of mediastinal fat. chest ct findings are helpful for making the initial diagnosis. to the authors' knowledge, the spectrum and follow-up ... | 2002 | 11818592 |
| anthrax: ent manifestations and current concepts. | in light of recent events, anthrax has once again taken center stage in the world of science and the world in which we live. because patients with anthrax may initially present to otolaryngology clinics, it is important for the otolaryngologist to know how to diagnose and treat this entity. this article will present current information on epidemiology, microbiology, pathogenesis/clinical manifestations, diagnosis, and treatment with a particular interest in the head and neck region. | 2002 | 11821758 |
| antibodies for defense against biological attack. | 2002 | 11821846 | |
| pinpointing anthrax-toxin inhibitors. | 2002 | 11821849 | |
| anthrax q & a. | 2002 | 11822179 | |
| anthrax: what you should know. | 2002 | 11822180 | |
| life goes on. | 2002 | 11823095 | |
| anthrax. 'borrowed immunity' may save future victims. | 2002 | 11823609 | |
| from the centers for disease control and prevention. evaluation of bacillus anthracis contamination inside the brentwood mail processing and distribution center--district of columbia, october 2001. | 2002 | 11824387 | |
| bioterrorism update: "maintain a high index of suspicion". | 2002 | 11845657 | |
| anthrax: safe treatment for children. | information regarding the treatment of anthrax infection is scarce in adults and is even more limited in children. children, however, may be at a greater risk for developing an infection and systemic disease if exposed to anthrax than adults. the centers for disease control and prevention (cdc) recommends the use of doxycycline or ciprofloxacin for prophylaxis and treatment in children. doxycycline currently is not indicated for use in children < 8 years old, due to staining of teeth and inhibit ... | 2002 | 11847958 |
| [anthrax as biological weapon and hospital infection control routines]. | 2002 | 11851275 | |
| fatal inhalational anthrax with unknown source of exposure in a 61-year-old woman in new york city. | a 61-year-old woman who was a new york city hospital employee developed fatal inhalational anthrax, but with an unknown source of anthrax exposure. the patient presented with shortness of breath, malaise, and cough that had developed 3 days prior to admission. within hours of presentation, she developed respiratory failure and septic shock and required mechanical ventilation and vasopressor therapy. spiral contrast-enhanced computed tomography of the chest demonstrated large bilateral pleural ef ... | 2002 | 11851577 |
| fatal inhalational anthrax in a 94-year-old connecticut woman. | we describe the 11th case of bioterrorism-related inhalational anthrax reported in the united states. the presenting clinical features of this 94-year-old woman were subtle and nondistinctive. the diagnosis was recognized because blood cultures were obtained prior to administration of antibiotics, emphasizing the importance of this diagnostic test in evaluating ill patients who have been exposed to bacillus anthracis. the patient's clinical course was characterized by progression of respiratory ... | 2002 | 11851578 |
| cutaneous anthrax associated with microangiopathic hemolytic anemia and coagulopathy in a 7-month-old infant. | a 7-month-old infant with cutaneous anthrax developed severe systemic illness despite early treatment with antibiotics. the infant displayed severe microangiopathic hemolytic anemia with renal involvement, coagulopathy, and hyponatremia. these findings are unusual with cutaneous anthrax, but have been described in illness resulting from spider toxin and may delay correct diagnosis. the systemic manifestations of the disease persisted for nearly a month despite corticosteroid therapy, but resolve ... | 2002 | 11851579 |
| bioterrorism preparedness and response: clinicians and public health agencies as essential partners. | 2002 | 11851584 | |
| [human anthrax outbreak due to cow anthrax in iwate prefecture]. | 2002 | 11852469 | |
| vaccines for adults in an age of terrorism. | vaccines are an effective, safe, and relatively inexpensive means of preventing infection; thus, they are important tools for fighting biological terrorism. two diseases, anthrax and smallpox, for which vaccines are not available to the general public are discussed. three other vaccines--tetanus toxoid, influenza vaccine, and hepatitis b vaccine--generally recommended for adults, may be in short supply as a result of recent acts of terrorism. | 2002 | 11852666 |
| bioterrorism: a primer for 2002. | the often anticipated, sometimes dismissed, threat of biological terrorism became a reality in the united states in the fall of 2001 with cases of cutaneous and inhalation anthrax. as the public health sector is rapidly focusing on enhancing awareness and preparedness, this overview is intended as a primer for clinicians. the more probable events, their most prominent characteristics, and currently available management strategies are summarized. the biowarfare characteristics of plague, tularemi ... | 2002 | 11852669 |
| biological warfare: implications for antimicrobial use. | biological warfare is intended to incapacitate a large number of individuals at a single exposure, creating epidemic-type disease, death, and social chaos. the organisms with potential for immediate use as bacteriologic weapons are bacillus anthracis, brucella melitensis, yersinia pestis, and vibrio cholera, all necessitating antibiotic therapy for a cure. it is reasonable, therefore, to assume that a biological attack, or even a hoax, would requiure thousands of individuals over a large area to ... | 2002 | 11853654 |
| risk of deliberately induced anthrax outbreak. | 2002 | 11853840 | |
| a recombinant carboxy-terminal domain of the protective antigen of bacillus anthracis protects mice against anthrax infection. | the immunogenicity and protective efficacy of overlapping regions of the protective antigen (pa) polypeptide, cloned and expressed as glutathione s-transferase fusion proteins, have been assessed. results show that protection can be attributed to individual domains and imply that it is domain 4 which contains the dominant protective epitopes of pa. | 2002 | 11854261 |
| [role of hormonal factors in pulmonary angiopathy development during anthrax-silicosis]. | the article represents results of radionuclide study of hormonal levels and pulmonary microcirculation in anthracosilicosis. the authors discuss mechanisms underlying influence of vasoactive hormones on pulmonary microcirculation. the authors revealed relationships between hormonal and vascular disorders in anthracosilicosis. | 2002 | 11855301 |
| from the centers of disease control and prevention. evaluation of postexposure antibiotic prophylaxis to prevent anthrax. | 2002 | 11855386 | |
| attacking anthrax. | 2002 | 11857900 | |
| response to bioterrorism. us anthrax incidents led to scares in scotland. | 2002 | 11858179 | |
| response to bioterrorism. screening for agents of bioterrorism increases terror. | 2002 | 11858180 | |
| response to bioterrorism. anthrax issue underlines need for infection specialists trained at bedside. | 2002 | 11858182 | |
| uncoupling of the cholera toxin-g(m1) ganglioside receptor complex from endocytosis, retrograde golgi trafficking, and downstream signal transduction by depletion of membrane cholesterol. | to induce toxicity, cholera toxin (ct) must first bind ganglioside g(m1) at the plasma membrane, enter the cell by endocytosis, and then traffic retrograde into the endoplasmic reticulum. we recently proposed that g(m1) provides the sorting motif necessary for retrograde trafficking into the biosynthetic/secretory pathway of host cells, and that such trafficking depends on association with lipid rafts and lipid raft function. to test this idea, we examined whether ct action in human intestinal t ... | 2002 | 11859071 |
| microbial genomics. tigr begins assault on the anthrax genome. | 2002 | 11859162 | |
| analytical chemistry. new test could speed bioweapon detection. | 2002 | 11859167 | |
| public health. is safe mail worth the price? | 2002 | 11859178 | |
| array-based electrical detection of dna with nanoparticle probes. | a dna array detection method is reported in which the binding of oligonucleotides functionalized with gold nanoparticles leads to conductivity changes associated with target-probe binding events. the binding events localize gold nanoparticles in an electrode gap; silver deposition facilitated by these nanoparticles bridges the gap and leads to readily measurable conductivity changes. an unusual salt concentration-dependent hybridization behavior associated with these nanoparticle probes was expl ... | 2002 | 11859188 |
| the microbiology laboratory's role in response to bioterrorism. | bioterrorism has existed since before the 14th century; however, the specter of such an attack is much greater today than ever before. technical expertise in microbiology and molecular testing, combined with the rapidity of worldwide air travel, has ensured that no geographic area would be untouched in a widespread attack. clinical microbiology laboratories will play a pivotal role in the detection of attacks involving weapons of mass destruction. | 2002 | 11860302 |
| traditions, anthrax, and children. | anthrax is sporadically seen in turkey, especially among people who live in rural areas and who come in contact with animals. two siblings with cutaneous anthrax are described in this report. a week before their admission to the hospital, contaminated cow's blood was smeared on their foreheads as part of a traditional ritual. both children were successfully treated with crystalline penicillin. in developing countries, traditions such as blood smearing may be an important factor in the transmissi ... | 2002 | 11860568 |
| the space race and biodefense: lessons from nasa about big science and the role of medical informatics. | the events that followed the launch of sputnik on oct 4, 1957, provide a metaphor for the events that are following the first bioterroristic case of pulmonary anthrax in the united states. this paper uses that metaphor to elucidate the nature of the task ahead and to suggest questions such as, can the goals of the biodefense effort be formulated as concisely and concretely as the goal of the space program? can we measure success in biodefense as we did for the space project? what are the existin ... | 2002 | 11861624 |
| anthrax vaccine offered, but not recommended, as option to treat infection. | 2002 | 11862627 | |
| desktop boost to anthrax studies. | 2002 | 11864578 | |
| evaluation of inhalational anthrax. | 2002 | 11866635 | |
| evaluation of inhalational anthrax. | 2002 | 11866636 | |
| apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. | lethal factor, the principal virulence factor of bacillus anthracis, inhibits mitogen-activated protein kinase (mapk) signaling by proteolytically cleaving mapk kinases. edema factor, another component of anthrax toxin, is an adenylate cyclase, which increases intracellular camp. inhibition of mapk signaling with either anthrax lethal toxin (letx) or small molecule mapk kinase inhibitors triggers apoptosis in human melanoma cells. normal melanocytes do not undergo apoptosis in response to mapk i ... | 2002 | 11867750 |
| bush moves to tighten security around scientific research. | 2002 | 11872544 | |
| the agenda shifts to health care protection. | 2002 | 11873441 | |
| bacillus anthracis infection in irradiated mice: susceptibility, protection, and therapy. | 2002 | 11873486 | |
| nuclear, biological, and chemical combined injuries and countermeasures on the battlefield. | the armed forces radiobiological research institute (afrri) has developed a research program to determine the major health risks from exposure to ionizing radiation in combination with biological and chemical warfare agents and to assess the extent to which exposure to ionizing radiation compromises the effectiveness of protective drugs, vaccines, and other biological and chemical warfare prophylactic and treatment strategies. afrri's defense technology objective md22 supports the development of ... | 2002 | 11873528 |
| patient safety alert. anthrax outbreak forces closer focus on patient safety. | 2002 | 11873646 | |
| anthrax meningitis: case report and review. | we report a case of meningitis caused by bacillus anthracis. although this agent appears to be a rare pathogen, it should always be considered in the differential diagnosis of haemorrhagic meningitis cases owing to the high mortality rate associated with it. | 2002 | 11874170 |
| emergency preparedness: the world trade center and singapore airline disasters. | 2002 | 11874787 | |
| bioterrorism becomes one of the hottest us research fields. | 2002 | 11875468 | |
| man bites dog. | 2002 | 11875510 | |
| anthrax. | anthrax is caused by bacillus anthracis, an encapulated and spore-forming bacillus. the disease is usually contracted through uptake of spores that remain viable in the contaminated soil for many years. anthrax is primarily a disease of herbivorous animals and is uncommon in humans who may get the infection through contact with contaminated animals or their products. anthrax spores germinate after entering the body through skin abrasions (cutaneous anthrax) or by inhalation (inhalation anthrax) ... | 2002 | 11876121 |
| anthrax inhalation and lethal human infection. | 2002 | 11879895 | |
| anthrax inhalation and lethal human infection. | 2002 | 11879896 | |
| bioterrorism and physicians. | 2002 | 11881175 | |
| [the anthrax bacterium--a biological masterpiece with deadly potential]. | 2002 | 11881219 | |
| patient information sheet: anthrax. | 2002 | 11883057 | |
| distinguishing influenza-like illness from inhalational anthrax. | 2002 | 11883060 | |
| prevention of inhalational anthrax in the u.s. outbreak. | 2002 | 11884746 | |
| from the centers for disease control. status of us department of defense preliminary evaluation of the association of anthrax vaccination and congenital anomalies. | 2002 | 11885583 | |
| genetic relationships of bacillus anthracis and closely related species based on variable-number tandem repeat analysis and box-pcr genomic fingerprinting. | variable-number tandem repeats (vntr) analysis and box-repeat-based pcr (box-pcr) genomic fingerprinting were performed on 25 bacillus strains to investigate the genetic relatedness of bacillus anthracis to the closely related species. based on vntr analysis, all b. anthracis strains could be assigned to (vntr)(4), which is the most commonly found type in the world. interestingly, a (vntr)(2) was also observed in bacillus cereus kctc 1661 and with an exact match to the tandem repeats found in b. ... | 2002 | 11886745 |
| cdc chief koplan quits "the best job in public health". | 2002 | 11888602 | |
| homeopathy and infectious disease: controversies raised by the recent foot-and-mouth disease and anthrax outbreaks. | 2002 | 11890431 | |
| discovery of the anthrax toxin: the beginning of studies of virulence determinants regulated in vivo. | anthrax kills many animal species. it was used to prove koch's postulates in 1876. soon after that the classical bacterial toxins were produced in vitro, but up to 1950, a lethal toxin had not been demonstrated in either anthrax bacilli or filtrates from laboratory cultures. the cause of death had been an enigma for seventy years. during the 1950's, a toxin was recognized by examining bacteria and their products obtained from guinea pigs dying of anthrax. the toxin was found in their plasma and ... | 2002 | 11890538 |
| tnf receptor 1, il-1 receptor, and inos genetic knockout mice are not protected from anthrax infection. | anthrax produces at least two toxins that cause an intense systemic inflammatory response, edema, shock, and eventually death. the relative contributions of various elements of the immune response to mortality and course of disease progression are poorly understood. we hypothesized that knockout mice missing components of the immune system will have an altered response to infection. parent strain mice and knockouts were challenged with ld95 of anthrax spores (5 x 10(6)) administered subcutaneous ... | 2002 | 11890668 |
| anthrax concerns persist in the usa. | 2002 | 11892492 | |
| managing emotional fallout. parting remarks from america's top psychiatrist. interview by diane coutu. | last fall, the united states was brutally thrust into a new and dangerous world. as the twin towers of the world trade center collapsed and the pentagon burned, the horrible reality of terrorism seared the american consciousness. it touched more than the victims and their families; everyone who sat transfixed before the horrific images on tv lived through the trauma. in a sense, we were all eyewitnesses, and we must all cope with feelings of anger, stress, and anxiety. that poses a huge immediat ... | 2002 | 11894678 |
| improved anthrax vaccine is needed, claims report. | 2002 | 11895815 | |
| mucosal or parenteral administration of microsphere-associated bacillus anthracis protective antigen protects against anthrax infection in mice. | existing licensed anthrax vaccines are administered parenterally and require multiple doses to induce protective immunity. this requires trained personnel and is not the optimum route for stimulating a mucosal immune response. microencapsulation of vaccine antigens offers a number of advantages over traditional vaccine formulations, including stability without refrigeration and the potential for utilizing less invasive routes of administration. recombinant protective antigen (rpa), the dominant ... | 2002 | 11895967 |
| planning for the unthinkable. | 2002 | 11896629 | |
| clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. | 2002 | 11897081 | |
| health's role with anthrax. | 2002 | 11898266 | |
| the case for more active policy attention to health promotion. | until recently, when anthrax triggered a concern about preparedness in the public health infrastructure, u.s. health policy and health spending had been dominated by a focus on payment for medical treatment. the fact that many of the conditions driving the need for treatment are preventable ought to draw attention to policy opportunities for promoting health. following a brief review of the determinants of population health-genetic predispositions, social circumstances, environmental conditions, ... | 2002 | 11900188 |
| ambulatory medical visits among anthrax-vaccinated and unvaccinated personnel after return from southwest asia. | the department of defense launched a mandatory anthrax immunization program for military personnel in december 1997. this program has been criticized for many reasons, including concern over side effects. this study was designed to give a quick answer to the question of whether vaccinated persons who deployed to southwest asia were more likely to seek medical care upon their return than their unvaccinated counterparts. the results demonstrated that there was no greater risk for vaccinated person ... | 2002 | 11901567 |
| anthrax update. | 2002 | 11901645 | |
| bioterrorism watch. anthrax aftermath: adverse drug reactions, vaccine controversy undercut cdc extended treatment offer. | 2002 | 11905387 | |
| risk factors for multisymptom illness in us army veterans of the gulf war. | this research study examined the prevalence of symptoms and identified risk factors for reported symptoms among a group of army gulf war (gw) veterans. a survey was mailed to all members of the ft. devens cohort in 1997, representing the third assessment of a group that consisted of 2949 us army soldiers deployed to the gulf, and was studied initially in 1991. a total of 1290 subjects responded to the mailed survey; aggressive follow-up methods to address non-response bias were employed. subject ... | 2002 | 11911029 |
| recognition and management of anthrax. | 2002 | 11911136 | |
| recognition and management of anthrax. | 2002 | 11911137 | |
| recognition and management of anthrax. | 2002 | 11911138 | |
| despite finding anthrax vaccine useful, iom recommends seeking a better one. | 2002 | 11911739 | |
| relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among us army women. | substantial concern surrounds the potential health effects of the anthrax vaccine, particularly the potential adverse effects on reproductive processes. | 2002 | 11911758 |
| [robert koch (1843-1910): a life in the trenches (against microbes, against virchow, and against so many other things)---and an unexpected parallel with golgi]. | 2002 | 11912879 | |
| anthrax aftermath: adverse drug reactions, vaccine controversy undercut cdc extended treatment offer. | 2002 | 11912887 | |
| 20/20 hindsight. months after anthrax claimed the lives of several. americans, hospitals review their reaction to the event--and plan for future crises. | last fall, after a nation suffered the unthinkable attacks of sept. 11, a second wave of terror held americans in its grip. questions still surround a series of baffling cases of anthrax that shook new york and connecticut. each of the hospitals involved report that despite the unsolved mysteries posed by these events, they are more cautious and better-prepared for future bioterrorism attacks. | 2002 | 11913044 |
| anthrax outbreak in mago national park, southern ethiopia. | 2002 | 11913590 | |
| [on bioterrorism]. | 2002 | 11915677 | |
| anthrax vaccine is safe and effective-but needs improvement, says iom. | 2002 | 11918923 |